Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to ...

Asset Management One Co. Ltd. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.4% during ...

BioMarin Pharmaceutical BMRN is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close. In the last reported quarter, BMRN’s earnings beat estimates by 16.67%.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday. Other research analysts also ...

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the business.

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...